Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshiaki Nagatani

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Forensic Science International|June 8, 2013
Discrimination of cultivated silk and wild silk by conventional instrumental analysesYuji Matsuyama, Yoshiaki Nagatani, Toshiyuki Goto, et al.
The American Journal of Case Reports|May 10, 2026
A Case of Pernicious Anemia Induced by Atezolizumab in Hepatocellular Carcinoma and Renal Cell CarcinomaTakeshi Sugimoto, Gen Kanemori, Hirohumi Kanehira, et al.
Biochimica Et Biophysica Acta|November 18, 2005
Sodium-dependent glucose transporter reduces peroxynitrite and cell injury caused by cisplatin in renal tubular epithelial cellsAkira Ikari, Yoshiaki Nagatani, Mitsutoshi Tsukimoto, et al.
Molecular and Clinical Oncology|April 25, 2022
Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challengeTaku Nose, Yohei Funakoshi, Hirotaka Suto, et al.
Journal of Cancer Research and Therapeutics|September 16, 2021
Immunosuppressive effects and mechanisms of three myeloid-derived suppressor cells subsets including monocytic-myeloid-derived suppressor cells, granulocytic-myeloid-derived suppressor cells, and immature-myeloid-derived suppressor cellsYoshiaki Nagatani, Yohei Funakoshi, Hirotaka Suto, et al.
BMC Cancer|November 16, 2016
Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trialsYoshiaki Nagatani, Kohei Shitara, Hideaki Bando, et al.
BJS Open|February 9, 2026
Neoadjuvant FOLFOXIRI plus bevacizumab without radiotherapy for high-risk rectal cancer: multicentre phase II trialTakeru Matsuda, Yoshiaki Nagatani, Yohei Funakoshi, et al.
Anticancer Research|January 31, 2021
Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse EventsRyo Takai, Yohei Funakoshi, Hirotaka Suto, et al.
International Journal of Hematology|July 25, 2025
Humoral immunity after hematopoietic stem cell transplantation: evaluation by B-cell receptor repertoire analysisSakuya Matsumoto, Yohei Funakoshi, Kimikazu Yakushijin, et al.
Journal of Smooth Muscle Research = Nihon Heikatsukin Gakkai Kikanshi|March 30, 2013
Combined pH-impedance monitoring and high-resolution manometry of Japanese patients treated with proton-pump inhibitors for persistent symptoms of non-erosive reflux diseaseHiroshi Yamashita, Kiyoshi Ashida, Takumi Fukuchi, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Forensic Science International|June 8, 2013
Discrimination of cultivated silk and wild silk by conventional instrumental analysesYuji Matsuyama, Yoshiaki Nagatani, Toshiyuki Goto, et al.
The American Journal of Case Reports|May 10, 2026
A Case of Pernicious Anemia Induced by Atezolizumab in Hepatocellular Carcinoma and Renal Cell CarcinomaTakeshi Sugimoto, Gen Kanemori, Hirohumi Kanehira, et al.
Biochimica Et Biophysica Acta|November 18, 2005
Sodium-dependent glucose transporter reduces peroxynitrite and cell injury caused by cisplatin in renal tubular epithelial cellsAkira Ikari, Yoshiaki Nagatani, Mitsutoshi Tsukimoto, et al.
Molecular and Clinical Oncology|April 25, 2022
Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challengeTaku Nose, Yohei Funakoshi, Hirotaka Suto, et al.
Journal of Cancer Research and Therapeutics|September 16, 2021
Immunosuppressive effects and mechanisms of three myeloid-derived suppressor cells subsets including monocytic-myeloid-derived suppressor cells, granulocytic-myeloid-derived suppressor cells, and immature-myeloid-derived suppressor cellsYoshiaki Nagatani, Yohei Funakoshi, Hirotaka Suto, et al.
BMC Cancer|November 16, 2016
Clinical outcomes of patients with gastrointestinal stromal tumor in phase I clinical trialsYoshiaki Nagatani, Kohei Shitara, Hideaki Bando, et al.
BJS Open|February 9, 2026
Neoadjuvant FOLFOXIRI plus bevacizumab without radiotherapy for high-risk rectal cancer: multicentre phase II trialTakeru Matsuda, Yoshiaki Nagatani, Yohei Funakoshi, et al.
Anticancer Research|January 31, 2021
Serum Soluble Interleukin-2 Receptor as a Potential Biomarker for Immune-related Adverse EventsRyo Takai, Yohei Funakoshi, Hirotaka Suto, et al.
International Journal of Hematology|July 25, 2025
Humoral immunity after hematopoietic stem cell transplantation: evaluation by B-cell receptor repertoire analysisSakuya Matsumoto, Yohei Funakoshi, Kimikazu Yakushijin, et al.
Journal of Smooth Muscle Research = Nihon Heikatsukin Gakkai Kikanshi|March 30, 2013
Combined pH-impedance monitoring and high-resolution manometry of Japanese patients treated with proton-pump inhibitors for persistent symptoms of non-erosive reflux diseaseHiroshi Yamashita, Kiyoshi Ashida, Takumi Fukuchi, et al.
Pageof 3